Helping healthcare providers offer regenerative therapies safely, legally, and confidently.

A practical guide to evidence, FDA regulation, and better questions for your healthcare provider.

If you’ve been hearing more about stem cells lately, you’re not alone. Research is advancing, clinics are discussing regenerative medicine, and patients are trying to separate promising science from established treatment. The challenge is knowing which information to trust.

Not all stem cell treatments are the same

Stem cells differ in their properties and medical applications. Blood-forming stem cells have established uses in treating certain blood and immune disorders. Other proposed applications are still being studied. A treatment mentioned in a research paper or advertised by a clinic is not automatically proven safe and effective for a particular condition.

The FDA’s consumer alert on regenerative medicine products explains why patients should be cautious about unapproved stem cell and related products.

What does FDA-approved really mean?

“FDA registered,” “FDA compliant,” and “FDA approved” do not mean the same thing. FDA establishment registration is not approval of a specific product or treatment. Some human cellular and tissue-based products qualify for regulation under Section 361 and 21 CFR Part 1271 when they meet all applicable criteria; others are regulated as drugs or biological products and may require premarket approval.

The FDA’s tissue establishment registration guidance describes registration and listing requirements. Patients should ask about the specific product and proposed use, not just whether a laboratory is registered.

What about umbilical cord blood and other birth tissues?

Umbilical cord blood has established applications involving blood-forming stem cells. But umbilical cord tissue and other birth tissue-derived products can differ in composition, processing, intended use, and regulatory status. Their source alone does not prove they contain viable stem cells or that they are approved for a particular condition.

Five questions to bring to your appointment

1. What exactly is the product, where does it come from, and what does it contain?
2. Is this specific product FDA-approved for the proposed use? If not, what is its regulatory status?
3. What human clinical evidence supports this particular product and use?
4. What risks, uncertainties, and alternatives should I consider?
5. What documentation supports the product’s sourcing, processing, and handling?

Better questions build trust

Chuck Meeker, Ph.D., Esq., founder of Hyagen Medical, brings a science-and-law perspective to the need for clearer information. A guiding distinction in Hyagen’s education is simple: interest and evidence are not interchangeable, and neither are innovation and regulatory approval.

Patients deserve explanations that are specific, understandable, and grounded in evidence.

Learn more about regulatory education and responsible clinical practices at Hyagen Medical.

Sources and further reading

• FDA Consumer Alert on Regenerative Medicine Products
• FDA Tissue Establishment Registration and Listing
• Hyagen Medical

Stem cells are increasingly part of a national conversation that includes emerging medicine, patient choice, federal regulation, and appropriate access. As that conversation grows, so does the need for precision.

We appreciate STAT News continuing to examine this increasingly important national conversation. Media scrutiny is part of advancing a serious regulatory discussion, and it makes precision in how we communicate about stem cells even more important.

Media coverage has recently linked the developing stem cell policy conversation with peptides, MAHA, RFK Jr., and the broader political environment. Those connections may be understandable in a news cycle focused on federal health policy, but they should not become a substitute for understanding the distinct scientific and regulatory questions surrounding stem cells.

At Hyagen Medical, we believe the stem cell conversation should be defined on its own merits. That means keeping the focus on science, regulatory clarity, responsible clinical and commercial practices, transparent communication, and patient protection, rather than political personalities or affiliations.

Regulatory clarity is not the absence of regulation

Calls for regulatory clarity should not be confused with calls for reduced oversight. Clear rules help clinicians and industry understand their responsibilities, help regulators communicate expectations, and help the public distinguish between scientific interest, lawful availability, and FDA approval.

That distinction is especially important in regenerative medicine, where public interest can move faster than public understanding. Responsible communication requires being clear about the regulatory status of products and avoiding claims that exceed the available evidence or applicable regulatory framework.

Patient choice requires good information

People should be able to participate meaningfully in decisions about their own bodies. But meaningful choice depends on accurate information. Accessibility and patient autonomy are strongest when they exist alongside appropriate safeguards, responsible oversight, and transparent communication.

That is why patient choice and compliance should not be presented as opposing ideas. A responsible framework can value both.

Stem cells and peptides should not be treated as interchangeable

Peptides and stem cells may appear in the same larger discussion about emerging medicine, but they are different scientific and regulatory categories. Any future policy discussion should preserve those distinctions rather than assume that one category provides a ready-made regulatory template for the other.

The same principle applies to politics. Experts and industry stakeholders may participate in conversations with federal agencies and public officials without that participation constituting an endorsement of a political party, figure, administration, or movement. The standard should remain consistent regardless of who holds office: clear rules, responsible standards, and patient protection.

Approaching federal stem cell discussions with purpose

As stem cell regulatory and compliance discussions escalate in DC, its early positioning will matter. Its credibility should be established through the expertise of knowledgeable participants and the quality of its scientific and regulatory dialogue, with a clearly stated commitment to responsible access and patient protection.

These discussions should also have an identity of their own. Federal stem cell discussions should not be defined through a peptide affiliation, a political association, or a single regulatory outcome. Its value should come from bringing credible voices together to address the questions unique to this field.

The conversation ahead

Regenerative medicine will continue to attract attention from clinicians, researchers, policymakers, industry stakeholders, and the public. Media framing will vary. The responsibility of those participating in the conversation is to remain precise and consistent.

For Hyagen Medical, the principles are straightforward: regulatory clarity is not deregulation; patient choice should be informed; access should be responsible; and scientific and regulatory conversations should remain grounded in evidence, transparency, compliance, and patient protection.

About Hyagen Medical

Hyagen Medical is a regenerative medicine company focused on advancing regulatory clarity, responsible education, and compliance across the human cellular and tissue-based products (HCT/P) landscape. Hyagen works with clinicians and industry partners to support greater understanding of product classification, applicable regulatory pathways, quality standards, and responsible communication. Through education, training, and industry collaboration, Hyagen is committed to helping build a more transparent and responsibly informed regenerative medicine marketplace while supporting patient protection and responsible innovation in the United States.

Learn more at HyagenMedical.com.

Media Contact
Carrie Hill
Director, Public Relations and Business Development
Hyagen Medical
[email protected]
757.621.9319

Hyagen Medical founder Chuck Meeker, Ph.D., Esq., joins regenerative medicine leaders in Washington to examine how classification, regulatory clarity and responsible communication could shape the future of the field in the United States.

LEHI, Utah, Sept. 22, 2026 – Hyagen Medical announced that founder and president Chuck Meeker, Ph.D., Esq., participated in the PepMed 2026 Regenerative Health World Congress in Washington, joining regenerative medicine leaders for a discussion on regulatory clarity, responsible communication, and the future of stem cell therapy in the United States.

The event included the panel, “Beyond the Headlines: Can America Become the Stem Cell Capital of the World?” which examined whether America can become the stem cell therapy capital of the world and what role classification, domestic access, and regulatory understanding may play in that discussion.

Hyagen Medical said its participation reflected the company’s focus on product understanding, regulatory education, clinician training, responsible marketing, patient communication, and clinical implementation in regenerative medicine.

Regenerative medicine does not need bigger promises. It needs greater clarity.

Meeker said in commentary published ahead of the Congress.

Meeker joined Jimmy St. Louis of Agentis, Dominik Duscher, M.D., Ph.D., of MuseCell Innovations, and Brigham Buhler of Ways2Well and ReviveRx for the PepMed panel, “Beyond the Headlines: Can America Become the Stem Cell Capital of the World?” Travis Smith, D.O., FACEP, of HHS/OASH moderated the discussion.

The panel brought perspectives spanning science, clinical practice, health care entrepreneurship, patient access, domestic innovation, and regulatory understanding into the same conversation. PepMed framed the session around regulatory clarity, domestic access, and what happens if patients continue leaving the United States for care.

For Hyagen, that intersection was precisely the point.

Before clinicians communicate about regenerative products, Meeker has consistently argued they first need to understand what they are working with: what the product is, how it was processed, how it is classified, its intended use, and which regulatory framework applies.

Those distinctions matter because “stem cells” can function as a broad public-facing term for products and approaches that may differ in composition, processing, intended use, and regulatory status. Classification can affect what happens downstream, from processing and distribution to clinician education, patient communication, and responsible marketing.

Clarity before clinical application

Patients want information and access. Clinicians need understandable rules. Scientists and entrepreneurs continue advancing new technologies. Companies are deciding where to manufacture, invest, and build. At the same time, regulators, policymakers, and journalists are being asked to make sense of an increasingly complex field.

Hyagen’s compliance-first philosophy starts with a straightforward idea: clinicians should understand the products they work with and the regulatory responsibilities surrounding them before communicating and administering those products to patients.

That approach is central to Hyagen Medical’s work with regenerative medicine practices through product understanding, regulatory education, clinician training, responsible marketing, patient communication, and clinical implementation.

For Hyagen, the significance of the Washington conversation is not an argument for less oversight. It is an argument for greater clarity and understanding of the oversight that applies and continued examination of regulatory pathways responsible participants can understand and follow.

A U.S. opportunity

The United States has scientific expertise, experienced clinicians, research institutions, health care entrepreneurs, manufacturing capability, and regulatory infrastructure. Greater clarity around terminology, classification, processing, intended use, applicable regulatory pathways, and responsible communication can help connect those strengths.

It can help clinicians make better-informed decisions, give patients more context for evaluating what they are offered, and help responsible companies understand the environment in which they are expected to operate. It can also help journalists and policymakers distinguish scientific evidence and regulatory status from promotional claims.

For Meeker, the Washington discussion reinforced why Hyagen has made education, transparency, and compliance central to its role in regenerative medicine.

The future of regenerative medicine won’t be determined by who makes the biggest claims. It will be determined by who commits to highest standards.

PepMed did not resolve every question facing regenerative medicine, nor did every participant approach those questions from the same perspective. Instead, the Congress put scientists, clinicians, policymakers, entrepreneurs, and industry leaders in the same room to examine questions increasingly affecting all of them.

What do we mean when we say “stem cells”? How should different products be understood and classified? What do clinicians need to know before communicating with patients? And what will it take to support responsible regenerative medicine innovation, investment, and expertise in the United States?

For Hyagen Medical, those are conversations worth continuing, and Washington offered reason for optimism that they are increasingly happening in the right rooms.

About Hyagen Medical

Hyagen Medical is a regenerative medicine company focused on advancing regulatory clarity, responsible education, and compliance across the human cellular and tissue-based products (HCT/P) landscape. Hyagen works with clinicians and industry partners to support greater understanding of product classification, applicable regulatory pathways, quality standards, and responsible communication. Through education, training, and industry collaboration, Hyagen is committed to helping build a more transparent and responsibly informed regenerative medicine marketplace while supporting patient protection and responsible innovation in the United States.

Learn more at HyagenMedical.com.

Media Contact
Carrie Hill
Director, Public Relations and Business Development
Hyagen Medical
[email protected]
757.621.9319

Press Inquiries
Chuck Meeker
[email protected]
757.621.9319
Hyagen Medical, Lehi, Utah 84043

A Hyagen Medical Lunch & Learn with Chuck Meeker, Ph.D., Esq. and Dr. Harry Adelson, founder of Docere Clinics in Park City, Utah.

Hyagen Medical founder and president Chuck Meeker, Ph.D., Esq., sits down with Dr. Harry Adelson for a candid conversation on what modern stem cell therapy is, and what it is not.

From prolotherapy to birth tissue

Dr. Adelson traces his own path through regenerative medicine: prolotherapy in the late 1990s, platelet-rich plasma from 2004, bone marrow and adipose-derived cell concentrates from 2010, and allogeneic birth tissue products since 2022. Each step, he explains, came with trade-offs in harvesting, inflammation and patient comfort.

What is really inside a birth tissue product

Tissue-derived products are not purified populations of stem cells. Umbilical cord Wharton’s jelly, for example, is a structural matrix that also carries exosomes, hyaluronic acid, collagen, elastin, fibronectin, growth factors and cytokines. Chuck and Dr. Adelson discuss why that natural balance matters, and what can change when a product is fractionated into separate components.

Stem cells as delivery trucks

The conversation returns to a core Hyagen Medical idea: stem cells do not do the healing. They act as couriers for bioactive signaling molecules that support the body’s own repair processes. Dr. Adelson also explains why he favors image-guided injection directly into the problem tissue over intravenous delivery for musculoskeletal work.

Naturally derived or lab-expanded?

Many international offerings grow stem cells in culture to reach large cell counts. Chuck explains how extended culture can shift a cell’s gene expression away from its natural profile, and why that raises questions for regulators and for anyone evaluating a product.

Questions to ask before choosing a product

• Is the product naturally derived, or have the cells been expanded or altered in a lab?
• Is it a full and complete birth tissue product, or a fractionated one?

Educational content. This session is for general education only and is not medical advice. Clinical experiences described by the speakers are personal observations, not claims of efficacy.

Questions or want to get involved? Connect with Hyagen Medical.

Media Contact
Carrie Hill, Director, Public Relations
Hyagen Medical
[email protected]
757-621-9319

A Hyagen Medical Lunch & Learn LIVE with Chuck Meeker, Ph.D., Esq., founder and president of Hyagen Medical and advisory board member of the American Academy of Peptide Medicine.

Peptides and stem cells are both drawing attention across regenerative medicine, and both face shifting regulatory questions. In this live session, Chuck brings the two together in a fast primer, followed by audience questions.

Sourcing

Stem cells are purified from biological sources such as bone marrow, adipose tissue and birth tissues like umbilical cord blood and Wharton’s jelly. Some groups then expand them in lab culture, which makes them semi-synthetic. Peptides are short chains of amino acids made through synthesis. Most bulk peptide ingredients are produced overseas, tested in the U.S. for identity, purity and potency, then compounded.

How they act

Stem cells work as couriers. They deliver growth factors, cytokines and chemokines that signal the body to begin its own regenerative processes. Peptides are the signal itself: a single molecule designed to act on a specific receptor or pathway.

Common uses

Cellular and exosome products are used in musculoskeletal, aesthetic and other applications, where sterility and third-party testing are essential. Peptides are most often given as small subcutaneous injections, with oral options emerging.

State and federal compliance

States regulate the practice of medicine, so practitioners should confirm what their licensing board allows and document their vetting of every product, supplier and manufacturer. The FDA regulates products and manufacturing, and marketing language that implies unapproved treatment claims can create federal risk.

• Stem cell products: a small number are FDA-approved drugs. Others follow the 351 biologics license pathway, and most rely on the Section 361 HCT/P framework in 21 CFR Part 1271.
• Peptides: compounded under FDA rules for 503A pharmacies, which compound for individual prescriptions, and 503B outsourcing facilities. The session was recorded ahead of the FDA Pharmacy Compounding Advisory Committee meetings on July 23 and 24, which considered returning several peptides to Category 1.

From the live Q&A

• Can stem cells and peptides be used together? They work differently. Cellular products carry a broad mix of signaling molecules, while a peptide targets one pathway, so the choice depends on what the clinician is trying to address.
• How long do results take? Outcomes come from the body’s own regenerative processes. Some pathways take months, while anti-inflammatory responses can appear much sooner.
• Aging or injuries? Regenerative medicine aims to support the cellular pathways that decline with age, which is why people explore it for longevity as well as injury.

Educational content. This session is for general education only and is not medical or legal advice. Regulatory status of specific peptides may have changed since recording.

Have a topic you want covered in a future Lunch & Learn? Comment on the Hyagen Medical LinkedIn page or connect with us.

Media Contact
Carrie Hill, Director, Public Relations
Hyagen Medical
[email protected]
757-621-9319

A Conversation with Chuck Meeker, Ph.D., Esq. and Jimmy St. Louis.

Hyagen Medical founder Chuck Meeker, Ph.D., Esq., sits down with Jimmy St. Louis to talk about stem cells and regenerative medicine, in connection with the Regenerative Health World Congress in Washington, D.C., September 17–18, 2026.

Meeker also joins Jimmy St. Louis and Brigham Buhler on the PepMed 2026 panel, “The Next Frontier: Stem Cells and Regenerative Medicine.” Read the media advisory.

Partners and media are welcome to share this video using the links above. Each link opens this conversation directly on the Hyagen Medical site.

Media Contact
Carrie Hill, Director, Public Relations
Hyagen Medical
[email protected]
757-621-9319

Meeker will join Jimmy St. Louis and Brigham Buhler for a discussion on the regulatory distinctions clinicians, and the people covering this industry, need to understand.

WASHINGTON – “Stem cells” may be one of the most recognizable terms in regenerative medicine. It may also be one of the most misunderstood.

As interest in regenerative medicine continues to grow, Chuck Meeker, Ph.D., Esq., founder and president of Hyagen Medical, will join Jimmy St. Louis and Brigham Buhler at the PepMed 2026 Regenerative Health World Congress, Sept. 17–18 in Washington, for a timely discussion about where the industry is headed and what clinicians need to understand before they market regenerative products to patients.

The panel, “The Next Frontier: Stem Cells and Regenerative Medicine,” comes as physicians, regulators, policymakers, patients and media are all trying to make sense of a field where the same terminology can be used to describe very different products and regulatory circumstances.

That is where Meeker believes the conversation needs to begin.

Understanding the Product Comes First

Before a clinic can responsibly market a regenerative product, it needs to understand what the product is, how it is classified, how it is processed, its intended use, which regulatory framework applies, and what can and cannot responsibly be said about it.

A better disclaimer cannot fix a fundamental misunderstanding of the product.

And a state law addressing the practice of medicine does not necessarily answer the federal regulatory questions surrounding the product itself.

Where State and Federal Authority Meet

Those distinctions are becoming increasingly important. States traditionally regulate medical practice and professional licensure, while the U.S. Food and Drug Administration regulates drugs, biologics and human cells, tissues, and cellular and tissue-based products under federal law.

For clinics trying to navigate regenerative medicine, understanding where those authorities intersect, and where they do not, is part of building a responsible practice. For journalists covering the industry, the distinctions can also change the story.

What the Panel Will Explore

• Why calling something a “stem cell” product does not tell the whole regulatory story
• What clinicians should understand about classification, processing and intended use
• The difference between state regulation of medical practice and federal oversight of biologic products
• Where regenerative medicine marketing can get ahead of the underlying science or regulatory status
• Why responsible patient communication begins with understanding the product
• What recent regulatory conversations may signal for clinicians working across regenerative medicine

Meeker’s work through Hyagen Medical combines his background in science and law with regulatory education, clinician training, product understanding and practice implementation.

His message going into Washington is simple: regenerative medicine does not need bigger promises. It needs greater clarity.

The Panel: The Next Frontier: Stem Cells and Regenerative Medicine

The PepMed discussion brings together leaders with perspectives spanning regenerative medicine, health care entrepreneurship, regulatory education, product understanding and patient communication.

Travis Smith, HHR (Moderator)

Smith will moderate the discussion.

Chuck Meeker, Ph.D., Esq., Founder, Attorney and Scientist, Hyagen Medical; AAPM Medical Advisory Board

Meeker brings a combined science-and-law perspective to regenerative medicine, with a focus on helping clinicians understand product classification, regulatory requirements, responsible marketing and patient communication. His work through Hyagen Medical emphasizes understanding the product and its regulatory framework before determining how it should be represented to patients.

Jimmy St. Louis, CEO, Agentis Longevity; President, Personalized Health Association

St. Louis is a health care entrepreneur and executive whose work spans longevity, personalized health and regenerative medicine. He previously founded Regenerative Medicine Solutions and brings an operator’s perspective to the discussion about how emerging areas of medicine move from innovation into real-world clinical practice.

Brigham Buhler, Founder and CEO, Ways2Well / ReviveRx

Buhler is an entrepreneur in personalized and preventive health care whose work has focused on expanding access to data-driven health and wellness services. His perspective adds the experience of building and communicating directly to consumers in rapidly growing areas of personalized medicine.

Together, the panel will examine a deceptively simple question with increasingly important consequences for regenerative practices:

What exactly are we talking about when we say “stem cells,” and what does a clinician need to understand before marketing them?

The discussion will explore why product classification, processing, intended use and regulatory status matter; where state regulation of medical practice and federal product oversight differ; and why responsible communication with patients begins with understanding the product itself.

Event Details

Event: PepMed 2026 Regenerative Health World Congress
Dates: Sept. 17–18, 2026
Location: Four Seasons Hotel, Washington, D.C.
Panel: “The Next Frontier: Stem Cells and Regenerative Medicine”
Panelists: Chuck Meeker, Ph.D., Esq.; Jimmy St. Louis; Brigham Buhler
Moderator: Travis Smith, HHR

Media interviews with Chuck Meeker are available surrounding PepMed 2026.

About Hyagen Medical

Hyagen Medical works with regenerative medicine practices through a practice-transformation model centered on product understanding, regulatory education, clinician training, responsible marketing, patient communication and implementation. The company’s compliance-first philosophy starts with a straightforward idea: clinicians should understand the products they work with and the regulatory responsibilities surrounding them before communicating those products to patients.

Media Inquiries and Interview Requests

Carrie Hill
Director, Public Relations
Hyagen Medical
757-621-9319
[email protected]

Disclosure: Hyagen occasionally shares research and educational content from trusted organizations to support informed conversations about regenerative medicine. Unless otherwise noted, the research and opinions shared belong to the original source and were not conducted, funded, or sponsored by Hyagen. For transparency, Hyagen Founder Charles (“Chuck”) Meeker, Ph.D., Esq., serves on the Advisory Board of the American Academy of Peptide Medicine (AAPM).

Following heightened national attention on peptide medicine, physicians, researchers and policy leaders will convene in Washington to discuss science, patient safety and the future of responsible clinical innovation.

LEHI, Utah – The national conversation surrounding peptide and regenerative medicine is changing quickly.

Just weeks after the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee considered seven peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List, physicians, researchers, pharmacists and policy leaders are preparing to gather in Washington for the American Academy of Peptide Medicine’s annual conference.

The timing is significant.

Why the Timing Matters

The FDA’s two-day July meeting placed BPC-157-related substances, KPV-related substances, TB-500-related substances, MOTS-c-related substances, emideltide-related substances, Semax-related substances and Epitalon-related substances before the advisory committee for scientific and regulatory consideration.

The proceedings also highlighted a larger issue facing physicians and patients: innovation in this space is moving quickly, while the regulatory, scientific and clinical conversations surrounding it continue to evolve.

That is the environment in which the American Academy of Peptide Medicine, or AAPM, will convene its annual conference this September in Washington, bringing together clinicians, researchers and policymakers for scientific education, professional collaboration and policy engagement.

Among those contributing to the conversation will be Charles “Chuck” Meeker, Ph.D., Esq., founder and president of Lehi-based Hyagen Medical and a member of AAPM’s Advisory Board.

A Conversation Larger Than Any Single Peptide

For Meeker, the discussion extends well beyond any individual peptide, product or regulatory decision.

“The bigger question is how we responsibly move an emerging area of medicine forward,” Meeker said. “Physicians need good science, clear information and an understanding of the regulatory framework surrounding the work they are doing. Patients deserve that same level of transparency. Those things have to move forward together if we want to build long-term trust in regenerative medicine.”

Science, Law and Regulation in One Perspective

Meeker brings an uncommon combination of experience to that discussion. A cancer biologist, biochemist and practicing attorney, he has spent more than a decade working at the intersection of science, intellectual property and FDA regulatory strategy.

Through Hyagen Medical, Meeker works with healthcare providers navigating regenerative medicine and birth tissue-derived products, with an emphasis on education, documentation, regulatory compliance, responsible communication and patient safety.

That compliance-first approach has become increasingly relevant as regenerative medicine has grown in both public visibility and patient interest.

Compliance as a Starting Point, Not an Afterthought

For Hyagen, the opportunity is not simply to help clinics participate in an emerging area of healthcare. It is to help providers understand the responsibilities that come with it, from product sourcing and regulatory classifications to clinical education, documentation and the claims clinics make when communicating with patients and the public.

Meeker’s involvement with AAPM extends that philosophy into the broader peptide medicine conversation. As an Advisory Board member, he contributes to the organization’s efforts around professional education, regulatory awareness and responsible standards as the field develops.

What the Advisory Committee Does, and What It Does Not Do

The July PCAC proceedings illustrate how active that conversation has become.

PCAC advises the FDA on scientific, technical and medical issues involving drug compounding, including substances considered under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Its recommendations provide expert input to the FDA but are nonbinding and do not themselves constitute FDA approval or a change in federal law.

That distinction is particularly important at a moment when regulatory developments can quickly become simplified, or overstated, in social media posts, patient conversations and healthcare marketing.

Education as the Field’s Greatest Responsibility

“One of the greatest responsibilities we have right now is education,” Meeker said. “There is tremendous interest in this field, but interest and evidence aren’t interchangeable, and neither are innovation and regulatory approval. Providers need to understand those distinctions and be able to communicate them clearly to patients.”

That message has become central to Hyagen’s work.

The company has increasingly focused on helping regenerative medicine practices build sustainable programs from the inside out, combining scientific education with regulatory understanding, documentation and compliant communication rather than treating compliance as something addressed after a clinic begins offering services.

Why These Conversations Matter Beyond September

It is also why the conversations taking place through AAPM matter beyond the walls of a September conference.

As federal regulators continue evaluating peptide-related substances and physicians respond to increasing patient interest in regenerative and longevity medicine, the decisions being discussed today could influence how this field develops for years to come.

Bringing scientists, physicians, pharmacists, attorneys and policymakers into the same conversation is an important part of getting that future right.

Frequently Asked Questions

What is the Pharmacy Compounding Advisory Committee?

PCAC advises the FDA on scientific, technical and medical issues involving drug compounding, including substances considered under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Does an advisory committee review mean a peptide is FDA approved?

No. PCAC recommendations provide expert input to the FDA. They are nonbinding and do not themselves constitute FDA approval or a change in federal law.

What is the American Academy of Peptide Medicine?

AAPM is a national organization that brings together physicians, researchers, pharmacists and policymakers for scientific education, professional collaboration and policy engagement across peptide medicine. Its annual conference will be held this September in Washington.

What is Hyagen Medical’s role in this conversation?

Hyagen works with healthcare providers on the education, documentation and regulatory framework behind regenerative medicine programs, with an emphasis on responsible communication and patient safety.

About Charles “Chuck” Meeker, Ph.D., Esq.

Charles “Chuck” Meeker, Ph.D., Esq., is a cancer biologist, biochemist, practicing attorney and founder and president of Hyagen Medical. With more than a decade of experience advising innovators and healthcare organizations, his work sits at the intersection of biologic science, intellectual property, FDA regulatory strategy and regenerative medicine.

Meeker also serves on the Advisory Board of the American Academy of Peptide Medicine, where he contributes to conversations surrounding professional education, regulatory awareness and responsible advancement of peptide medicine.

About Hyagen Medical

Hyagen Medical is a compliance-first regenerative medicine company based in Lehi, Utah. The company works with healthcare providers to pair biologic products with the education, documentation and regulatory framework needed to responsibly implement regenerative medicine programs.

Hyagen’s approach emphasizes scientific integrity, regulatory understanding, transparent communication and patient safety, helping providers navigate an increasingly complex environment while building sustainable clinical programs.

Media Contact

Carrie Hill
Director, Public Relations
Hyagen Medical
757-621-9319
[email protected]

Editor’s Note: This article summarizes research published by the American Academy of Peptide Medicine (AAPM). Hyagen is sharing these findings as part of its commitment to evidence-based patient education.

WASHINGTON — The American Academy of Peptide Medicine (AAPM) hosted a live press availability on Monday, July 20, 2026, at 3:00 PM ET with peptide therapy experts to address the restoration of safe, regulated, physician- and pharmacist-supervised peptide therapies — days before the U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) two-day hearing on July 23–24.

In addition to peptide therapy regulation recommendations, pollster Kellyanne Conway will provide a briefing on the findings of a new, exclusive poll assessing public knowledge, attitudes, and opinions regarding peptide therapies.

Who

• Dr. Lee Rosebush – Chair, American Academy of Peptide Medicine
• Sara Totri – Chief Operating Officer, American Academy of Peptide Medicine
• Kellyanne Conway – Political consultant and pollster; former Senior Counselor to President Donald J. Trump
• Gary Brecka – Founder, The Ultimate Human
• Gov. Phil Bryant – Former Governor of Mississippi; Former Lieutenant Governor & State Auditor
• Gov. Ricardo Rosselló – Former Governor of Puerto Rico
• Dr. Jessica Duncan, M.D., D.A.B.O.M. – Chief Medical Officer, Ivim Health
• Dan Deneui – Chief Executive Officer, Evexias Health Solutions; Executive Managing Member, FarmaKeio Pharmacy Network
• Terri Deneui, DNP, APRN, ACNP-BC – Founder/Practitioner EVEXIAS Medical Centers; EVEXIAS Health Solutions & EvexiPEL
• Brigham Buhler – Founder and CEO, Ways2Well

Speaker lineup subject to change.

When

Monday, July 20, 2026 · 3:00 PM ET (remarks and live Q&A)

RSVP

The virtual press briefing is open to credentialed members of the media. Q&A with speakers will be provided following remarks. Interested members of the media should RSVP to [email protected] to receive the virtual briefing credentials and feed.

Why

In 2023, the FDA moved a group of widely used, naturally occurring peptides into a restricted category, sharply limiting physicians’ and pharmacists’ ability to prescribe and compound them for patients. Advocates say the restrictions did not reduce demand but instead pushed patients toward an unregulated global gray market of unverified vendors, raising costs and safety risks, particularly for Americans managing chronic illness.

As the FDA’s PCAC prepares to weigh whether these peptides should be returned to the pathway for regulated compounding on July 23–24, AAPM and its speakers will make the case for a safe, transparent, and science-driven peptide market.

Watch the full briefing →

Media Contact

Melody Seraydarian
[email protected]

About the American Academy of Peptide Medicine

The American Academy of Peptide Medicine (AAPM) is the official nonprofit academic society dedicated to advancing the responsible clinical use of peptide therapies. We unite physicians, researchers, pharmacists, and policymakers committed to evidence-based practice, rigorous education, and meaningful policy engagement in one of medicine’s fastest-growing disciplines. For more information, please visit pepmed.org.

Disclosure: Hyagen occasionally shares research and educational content from trusted organizations to support informed conversations about regenerative medicine. Unless otherwise noted, the research and opinions shared belong to the original source and were not conducted, funded, or sponsored by Hyagen. For transparency, Hyagen Founder Charles (“Chuck”) Meeker, Ph.D., Esq., serves on the Advisory Board of the American Academy of Peptide Medicine (AAPM).

LEHI, Utah – Hyagen Medical today announced that Founder and President Charles Meeker, Ph.D., Esq., has joined the Advisory Board of the American Academy of Peptide Medicine (AAPM), a national organization dedicated to advancing education, professional standards, and regulatory awareness throughout the peptide medicine community.

Meeker’s appointment reflects a shared commitment between Hyagen Medical and AAPM to promote regulatory clarity, strengthen professional education, and encourage transparent communication as peptide medicine, regenerative medicine, longevity science, and biologic innovation continue to evolve.

While joining the Advisory Board is a professional milestone, Meeker believes the larger story is about the future of a rapidly evolving field.

Innovation Is Accelerating. Education Must Keep Pace.

Over the past several years, public interest in peptide medicine, regenerative biologics, longevity science, and wellness medicine has expanded dramatically. Conversations that once took place primarily among physicians, researchers, and scientists are now happening on podcasts, social media, healthcare conferences, and inside clinics across the country.

Greater awareness creates opportunity. It also creates responsibility.

As scientific discovery continues to advance, education, regulatory understanding, and professional communication must evolve alongside it. Without clear standards and accurate information, confusion can outpace understanding.

“The science is not what concerns me,” said Meeker. “Science is supposed to evolve. What truly concerns me is when public enthusiasm begins moving faster than public understanding. That’s where confusion starts. That’s where unrealistic expectations begin. And ultimately, that’s where patients can be put at risk.”

Why the American Academy of Peptide Medicine Matters

The American Academy of Peptide Medicine was established to help advance education, professional standards, and regulatory awareness throughout the peptide medicine industry.

By bringing together physicians, scientists, educators, regulatory professionals, and industry leaders, AAPM creates opportunities for thoughtful discussion around emerging science, evolving regulatory expectations, and responsible professional communication.

Its mission reflects something many healthcare leaders recognize: long-term credibility is built through education, transparency, accountability, and a commitment to high professional standards.

For Meeker, that mission closely aligns with Hyagen Medical’s own commitment to advancing regulatory clarity and professional education.

“We’ve always believed that trust is earned through transparency,” he said. “The future of regenerative medicine won’t be determined by who makes the biggest claims. It will be determined by who commits to the highest standards.”

One principle has consistently guided Hyagen Medical’s approach: words matter.

Accurate scientific communication, responsible marketing, and thoughtful patient education help build trust between clinics, healthcare professionals, and the patients they serve. Clear communication supports informed decision-making and strengthens confidence throughout the regenerative medicine community.

Why Regulatory Education Has Become Increasingly Important

As regenerative medicine and peptide medicine continue to grow, regulatory education has become increasingly important for healthcare organizations seeking to operate responsibly.

Federal agencies, including the FDA and FTC, have taken enforcement actions against organizations that marketed unproven regenerative medicine products or made claims that exceeded current regulatory requirements.

These actions reinforce an important principle: regulatory compliance and responsible communication are essential components of professional healthcare practice.

These enforcement actions underscore the importance of helping healthcare professionals understand regulatory expectations, communicate accurately, and build lasting patient trust. The lessons from these cases are not about assigning blame.

“The vast majority of clinic owners are trying to do things the right way,” Meeker said. “They’re navigating a field that’s evolving quickly while patients are asking more informed questions than ever before. Education provides clarity, and clarity builds confidence.”

The Shared Mission of Hyagen Medical and AAPM

Although Hyagen Medical and AAPM serve different roles within the industry, both organizations recognize that education is fundamental to long-term success.

Hyagen Medical is committed to helping clinics, healthcare professionals, and industry partners navigate an evolving regulatory landscape through education, regulatory clarity, and transparent communication. By working with manufacturing partners operating within applicable federal regulatory frameworks, Hyagen supports healthcare professionals seeking educational resources and information about biologic products within those regulatory frameworks.

AAPM complements that mission by encouraging continuing education, professional collaboration, and informed discussion among physicians, scientists, educators, and regulatory professionals working throughout peptide medicine.

Together, these efforts contribute to a stronger professional community built on regulatory clarity, clinical integrity, transparent communication, and informed decision-making.

The Perspective of Chuck Meeker

As both a scientist and attorney, Charles Meeker, Ph.D., Esq. has spent his career working where biology, healthcare innovation, intellectual property, business strategy, and regulatory compliance intersect.

His experience provides a practical perspective on the challenges facing practitioners, manufacturers, clinics, researchers, and healthcare organizations as regenerative medicine continues to evolve.

Through his advisory role with AAPM, Meeker will contribute to ongoing conversations surrounding:

• Regulatory education
• Professional standards in peptide medicine
• Transparent clinic communication
• Patient education
• Healthcare marketing compliance
• Emerging regulatory issues affecting regenerative medicine
• Long-term credibility across peptide medicine and regenerative healthcare

These conversations are not simply about regulations. They are about trust.
Trust between practitioners and patients.
Trust between science and communication.
Trust between innovation and accountability.

Frequently Asked Questions

What is the American Academy of Peptide Medicine?

The American Academy of Peptide Medicine (AAPM) is a professional organization dedicated to advancing education, professional standards, and regulatory awareness by bringing together physicians, scientists, educators, and industry professionals involved in peptide medicine. For additional information about the Academy and its educational initiatives, visit the American Academy of Peptide Medicine.

Why did Charles Meeker join the Advisory Board?

Meeker accepted the appointment because it aligns closely with Hyagen Medical’s commitment to regulatory clarity, professional education, transparent communication, and advancing thoughtful dialogue throughout regenerative medicine and peptide medicine.

Why are professional standards important in peptide medicine?

As scientific research, public awareness, and clinical interest continue to grow, professional standards help support accurate communication, informed decision-making, and a shared understanding of evolving regulatory expectations.

What makes Hyagen Medical different?

Hyagen Medical is a compliance-first education company focused on regulatory clarity, professional education, and transparent communication. The company develops educational resources designed to help clinics and healthcare professionals better understand evolving regulatory frameworks and responsible communication practices.

Looking Ahead

The future of peptide medicine and regenerative healthcare will continue to develop as science, education, and regulatory understanding evolve.

Scientific discovery will continue.
Technology will continue to evolve.
Public interest will continue to grow.

The opportunity before the industry is to ensure that education, regulatory awareness, and professional standards continue advancing alongside innovation. That shared commitment is what connects Hyagen Medical and the American Academy of Peptide Medicine.

Not to slow innovation. But to help ensure progress is supported by transparency, clinical integrity, informed decision-making, and responsible professional communication.

As regenerative medicine, peptide medicine, longevity science, and biologic innovation continue to evolve, education will remain one of the industry’s most valuable assets. Hyagen Medical believes that regulatory clarity, transparent communication, and professional standards help create an environment where healthcare professionals can make informed decisions and patients can better understand an increasingly complex field. Through collaboration with organizations such as the American Academy of Peptide Medicine, Hyagen remains committed to contributing to thoughtful dialogue and elevating standards across the profession.

About Charles Meeker, Ph.D., Esq.

Charles Meeker is the Founder and President of Hyagen Medical. As both a scientist and attorney, he advises healthcare organizations on biologic science, regulatory strategy, intellectual property, and responsible industry practices. His work focuses on advancing regulatory education, strengthening professional standards, and helping healthcare organizations navigate the evolving regenerative medicine landscape.

Learn More

Whether you are a physician, clinic owner, healthcare professional, or someone seeking trusted educational resources, Hyagen Medical is committed to advancing regulatory clarity, professional education, and transparent communication throughout regenerative medicine.

Visit Hyagen Medical to explore educational resources, learn about the Hyagen Gold Standard Certification program, and discover additional information designed to support responsible clinical practice. To learn more about Charles Meeker, Ph.D., Esq., connect with him on LinkedIn.

Media Contact

Carrie Hill
Director, Public Relations
Hyagen Medical
757-621-9319
[email protected]

Regenerative medicine is one of the fastest-moving beats in modern healthcare where innovation, regulation, patient safety, and marketing claims collide. If you're a journalist, producer, editor, or podcast host covering stem cells and biologics, you need credible sources fast, especially when you're on deadline.

That's why Hyagen Medical created a downloadable Media Kit a press-ready resource built to help you develop accurate angles, verify context, and book expert interviews without the usual back-and-forth.

What you'll find inside the Hyagen Medical Media Kit

The Hyagen Medical Media Kit is designed for speed, clarity, and accuracy. It includes:

• Approved Hyagen Medical overview (what Hyagen Medical is, and what it does in the regenerative medicine industry)
• Expert bio + credentials for Chuck Meeker (Ph.D., Esq.), Founder & President
• Suggested story angles + interview topics (regenerative medicine, FDA/FTC standards, ethical marketing, patient trust)
• Media statistics and impact highlights (reach and training footprint)
• Press-ready brand assets (logos + quick reference material)
• Direct contact info for interviews and media requests

"As Seen On": Chuck Meeker's media features

If you're looking for a credible expert voice who can translate complex stem cell and compliance issues into clear, usable commentary, the one-sheet inside the Media Kit includes Chuck's "As Seen On" section, featuring:

• Science Journal
• ABC4 News
• The Ultimate Assist

The one-sheet also notes an upcoming feature: Make America Great with Robert F. Kennedy Jr.

Why Hyagen Medical is relevant to your coverage

Hyagen Medical™ is positioned as a training and certification authority focused on regenerative medicine compliance, clinic education, and patient protection especially where the industry is vulnerable: claims, sourcing, transparency, and regulatory alignment.

From the Media Kit one-sheet highlights:

• 100+ clinics trained in FDA-compliant practices
• 19M+ media audience reached
• $1.2M+ in regulatory legal fees saved through compliance education and strategy

If your story touches enforcement, consumer protection, evolving standards, ethical marketing, or the difference between hype and evidence Hyagen Medical's Media Kit gives you a solid foundation fast.

Download the Hyagen Medical Media Kit (and book fast if you're on deadline)

You can download the Media Kit directly from Hyagen Medical's Media page. If you're working on a story and need quick turnaround, send your deadline and angle and we'll respond quickly.

Media Contact: [email protected]
Media Phone: 757-621-9319

Frequently Asked Questions

What is the Hyagen Medical Media Kit?

A downloadable press resource for journalists covering regenerative medicine, stem cell therapy regulation, clinic compliance, and patient safety.

Who is Chuck Meeker?

Chuck Meeker (Ph.D., Esq.) is Hyagen Medical's Founder and President, known for simplifying regenerative medicine compliance, ethical marketing, and regulatory strategy.

What's included in the Hyagen Medical press kit?

Press-ready bios, "As Seen On" media placements, story angles, fast facts, logos, and booking/contact info.

How do I request an interview with Hyagen Medical?

Use the media contact information in the Media Kit or reach out via the Media page contact pathway with your deadline and topic.

What topics can Hyagen Medical comment on?

The real state of stem cell clinics in the U.S., where hype ends and regulation begins, and how ethical transparency can rebuild patient trust in regenerative medicine.

FDA regulatory frameworks have not changed. At the same time, peptide substances remain under active federal review, and visibility is increasing.

FDA 503A Update: Peptides Remain Under Evaluation

The FDA's latest update to the 503A bulk drug substances list reinforces that many peptides are still within formal regulatory review processes, not approved for broad clinical use. Key highlights include updates across three categories:

• Category 1: Bulk drug substances under evaluation
• Category 2: Substances that raise significant safety concerns
• Category 3: Substances nominated without adequate support

Removal of multiple peptide substances from Categories 1 and 2 due to withdrawn nominations, including: BPC-157, Thymosin Beta-4 (TB-500), Melanotan II, GHK-Cu, KPV, MOTs-C, Semax, and Epitalon.

The update also confirms that the FDA will consult the Pharmacy Compounding Advisory Committee (PCAC) throughout 2026–2027 regarding potential inclusion of these substances on the 503A bulks list. These updates do not indicate approval, expanded access, or regulatory clearance. They reflect ongoing evaluation within established FDA compounding and drug review frameworks.

What This Means for Peptide Regulation

For clinics and providers, the implications are clear:

• Peptide regulation remains governed by existing FDA pathways
• Section 503A compounding rules still apply
• Marketing, classification, and communication standards have not changed

Public attention regardless of source does not alter what substances can be compounded, how products can be described, or what claims can be made to patients. Regulatory status is determined through FDA review not public discourse.

The Growing Risk: Visibility Without Alignment

As peptides re-enter public conversation, Hyagen Medical is observing a widening gap between what is being discussed publicly and what is permitted under current regulation. This gap creates measurable risk for clinics:

• Non-compliant marketing language
• Misclassification of compounded substances
• Patient communication that exceeds regulatory boundaries

Increased visibility may lead to increased scrutiny particularly in how clinics communicate about peptides.

The Hyagen Medical Standard: Compliance-First Education and Distribution

Hyagen Medical operates as a compliance-first partner to clinics nationwide, providing:

• Training aligned with FDA regulatory frameworks, including 503A compounding requirements
• Structured, compliant communication strategies
• Distribution standards focused on sourcing transparency and clinical integrity

The company's framework is grounded in a clear principle: Clarity in mechanism. Precision in language. Accountability in practice.

Industry Leadership at the Regulatory Level

Hyagen Medical's presence in Washington, D.C. reflects its commitment to engaging in ongoing regulatory dialogue as the peptide and biologics landscape evolves. Founder and President Chuck Meeker brings a dual background in science and law, providing a practical perspective on how clinics can operate within existing frameworks.

"As attention increases, the need for accuracy becomes more important not less. This is not a moment of expanded permission. It is a moment that requires clear understanding of what is allowed today." Chuck Meeker

A Call to Clinics: Align Before Enforcement Increases

Hyagen Medical advises clinics to approach this environment with discipline. The clinics best positioned moving forward will be those that:

• Understand FDA 503A compounding regulations
• Communicate within clearly defined boundaries
• Align operations with current not assumed regulatory standards

Hyagen Medical works with clinics across the United States to provide the education, structure, and support needed to operate compliantly within the evolving peptide and regenerative medicine landscape. Visit www.hyagenmedical.com to learn more.

Media Contact: Carrie Hill, Hyagen Medical Press & Communications [email protected]

Lehi, UT February 10, 2026 FDA compliance for regenerative medicine clinics is becoming the defining factor between sustainable growth and regulatory exposure. As patient demand for stem cell therapy and regenerative biologics expands nationwide, so does scrutiny from regulators, payment processors, and certification bodies. Clinics operating in this space must now demonstrate clear alignment with FDA 21 CFR Part 1271, 361 HCT/P standards, and compliant patient communication practices.

To address this growing need, Hyagen Medical has launched a National FDA Compliance and Education Initiative designed to help regenerative medicine clinics reduce regulatory risk, strengthen documentation systems, and elevate patient education standards. This initiative positions compliance not as a restriction but as a competitive advantage.

"Regenerative medicine doesn't need louder voices it needs clearer ones. Stem cells are politically agnostic. The real work is helping providers and patients understand what is compliant, ethical, and accurate." Chuck Meeker, Ph.D., Esq., Founder of Hyagen Medical

Why this matters now

As regenerative medicine becomes more visible to consumers, clinics face growing pressure to balance innovation with compliance. Confusion around appropriate claims, sourcing language, and regulatory boundaries has increased risk across the industry for providers and patients alike. Hyagen Medical was built to address that gap by standardizing compliance education and supporting transparent, well-documented patient conversations grounded in existing FDA frameworks.

"The biggest risk we see isn't innovation it's misinformation. When education is missing, trust erodes. Our role is to help clinics lead with clarity before problems arise." Chuck Meeker

Compliance-first as a credibility engine

Hyagen Medical works at the intersection of regulatory guidance, provider training, and patient-facing education. Its compliance-first model helps clinics:

• Navigate FDA regulatory boundaries with confidence
• Reduce exposure to risk from misleading claims or noncompliant marketing
• Strengthen informed consent and patient understanding
• Build long-term credibility in a rapidly evolving biologics landscape

Rather than treating regulation as a constraint, Hyagen Medical positions compliance as the foundation for sustainable growth in regenerative medicine.

Politically neutral, education-driven by design

Hyagen Medical maintains a deliberately neutral stance in public discourse, emphasizing that regenerative medicine and stem cell science are not political issues, but matters of patient safety, ethical sourcing, and regulatory clarity. By prioritizing accurate language, transparent education, and adherence to FDA guidance, Hyagen Medical aims to elevate both industry standards and public trust.

Product alignment and regulatory clarity

In addition to education and consulting, Hyagen Medical distributes regenerative biologics, including HCT/P allograft products positioned under FDA “361 HCT/P” and AATB guidelines. Products are clearly described as minimally manipulated and intended for homologous use only reinforcing the company's commitment to compliant positioning and responsible clinical use.

Outcomes Hyagen Medical aims to support

• Clearer, more consistent patient education and informed consent
• Increased provider confidence navigating regulatory frameworks
• Reduced regulatory and reputational risk across practices
• Stronger, credibility-led adoption of regenerative medicine therapies

For journalists covering regenerative medicine, biologics, or health policy

Hyagen Medical and Founder Chuck Meeker are available for expert commentary on:

• FDA compliance and regenerative medicine regulation
• Patient education and informed consent best practices
• Ethical implementation of stem cell and biologics therapies
• Separating science from misinformation in public health conversations

This release addresses the FDA compliance requirements for regenerative medicine clinics and patient education. Interview requests are available upon request.

About Hyagen Medical

Hyagen Medical is a regenerative medicine compliance and education company headquartered in Lehi, Utah. Founded by Chuck Meeker, the company supports healthcare providers nationwide through FDA-aligned training, regulatory consulting, biologics distribution, and patient education systems designed to promote ethical, compliant, and transparent regenerative medicine practices.

Press inquiries: Carrie Hill, Head of Public Relations media [at] hyagenmedical.com

Marketing regenerative medicine is high-risk if your claims outpace evidence or policy. Here's how to stay educational, compliant, and discoverable.

In this Grow Smarter podcast interview with Hyagen Medical Founder Chuck Meeker, host Andrew Hong, Founder of Tobe Agency, dives deeper into Hyagen Medical's practical, compliance-first training guide for regenerative medicine brands: including safer messaging, claim boundaries, Google policy realities, and PR strategies that build trust.

If you work in regenerative medicine, you already know the truth: marketing is where innovation meets scrutiny. The minute your website language reads like a promise to treat a disease, you're no longer "just educating" you may be signaling product intent in a way regulators and platforms evaluate aggressively. This guide is built for clinics, founders, marketers, and journalists covering the space. It's compliance-first: not how to "evade" rules but how to communicate responsibly, earn trust, and stay discoverable.

Important note: This is general information, not legal advice. Regenerative medicine regulation is complex. Consult qualified FDA/regulatory counsel for your specific products, procedures, sourcing, and claims.

Why Stem Cell Marketing Gets Flagged So Easily

1. The FDA looks at what you imply, not just what you sell

FDA guidance makes clear that labeling and advertising can reflect a company's "objective intent," including whether something is being promoted for non-homologous use or outside criteria for certain regulatory pathways. Translation: your website copy, blog posts, patient testimonials, videos, and even "conditions we treat" pages can become part of how your intent is interpreted.

2. Enforcement is real and public

FDA has issued warning letters and notices to companies marketing unapproved or noncompliant stem-cell-related offerings, often citing disease claims and unapproved product marketing.

3. Google and other platforms have "speculative/experimental" filters

Google Ads restricts many promotions for speculative or experimental treatments, and it draws hard lines around what can be directly promoted versus what can be purely educational/informational. Industry groups have also raised concerns that "educational" language could be misused so platforms watch intent and landing page behavior closely.

4. The FTC cares about substantiation

Separately from FDA, the FTC expects marketers to have competent and reliable scientific evidence for health-related claims and to communicate limitations clearly when science is emerging.

The Compliance-First Messaging Framework (Use This)

Step 1: Replace "Treatments for Conditions" with "Education + Eligibility"

High-risk: "We treat arthritis, spinal stenosis, neuropathy, autoimmune disease, and more." · "Avoid surgery with stem cells." · "Cures inflammation and chronic pain."

Lower-risk, more compliant positioning:

• "Regenerative medicine education and clinical consultation."
• "Patient eligibility and options review (including risks, benefits, evidence, and alternatives)."
• "Orthobiologics: what the research says, what's experimental, and what patients should ask."

Rule of thumb: You can educate about a topic; you should be extremely cautious about promising outcomes especially for named diseases.

Step 2: Use "Evidence Language," Not "Outcome Language"

Swap "Proven to regenerate cartilage" for "Research is ongoing. Some studies suggest potential benefits for certain orthopedic indications, and results vary." Swap "Guaranteed relief" for "Outcomes vary by patient, protocol, diagnosis, and overall health. A consult is required to determine candidacy." This aligns with what regulators and platforms expect: clarity, uncertainty disclosure, and avoidance of overpromising.

Step 3: Keep Testimonials and Stories "Non-Clinical"

Testimonials are powerful but they are also high-risk if they imply disease treatment or guaranteed outcomes. Safer testimonial structures:

• Experience-focused: scheduling, education, informed consent, staff professionalism
• Decision-focused: "I appreciated learning risks and alternatives before choosing a path."
• Recovery-focused without diagnosis claims: "I felt supported and had a positive experience."
• Avoid: named diseases + "it fixed/cured/treats" language.

Google Ads Reality: What's Most Likely to Work

Google's policy allows ads for FDA approved/licensed cell or gene therapies under specific conditions, and it also allows content that is exclusively educational or informational, regardless of approval status. So for many regenerative medicine brands, the practical path is the "Education-First Funnel": Ad → Educational landing page → Consult request (carefully framed).

Examples of education-first topics that can drive traffic without triggering immediate policy issues:

• "Stem cells vs PRP vs exosomes: what they are and what evidence exists"
• "Understanding FDA terminology: minimal manipulation, homologous use, HCT/P basics"
• "Questions every patient should ask before traveling for treatment"
• "How to evaluate a clinic's sourcing, protocols, and informed consent"

Avoid: direct ads that promise treatment outcomes for specific conditions, or landing pages that read like a disease-treatment menu.

A Safer Website Structure for Regenerative Medicine Brands

If you want search traffic without the "banned" triggers, structure your site like a resource center, not a claims page. Recommended site architecture:

• Start Here (Patient Education Hub): definitions, risks, realistic expectations, alternatives
• Regulatory & Safety Page: FDA language overview, compliance posture, sourcing transparency
• Evidence Library: summaries + links to peer-reviewed research, with clear "limitations" framing
• Consultation Page: what a consult includes, how eligibility is determined, who should not proceed
• Media Page (for journalists): expert bios, interview topics, prior media, data points, contact

"Red Flag" Phrases That Commonly Trigger Scrutiny

Avoid or heavily qualify: "cure," "treat," "heal," "reverse," "regrow," "guarantee," "FDA approved" (unless it truly is, and for that exact product/indication), "proven," "clinically verified," "no risk," "no side effects," and long lists of diseases/conditions presented as services. Enforcement actions and public notices often cite disease-treatment marketing claims as a key issue.

The PR Strategy That Builds Authority (and Protects You)

If ads are restricted, PR and content often become the most durable growth engine. What works in regenerative medicine PR:

• Journalist-friendly explainers (science + policy + patient safety)
• Expert commentary on FDA language, enforcement trends, and consumer risk
• Data transparency: what you track, what you don't claim, what you disclose
• Myth vs reality series: medical tourism, exaggerated promises, and how patients can protect themselves

This is also where Hyagen Medical is positioned: education that protects patients and helps clinics communicate responsibly.

Quick Compliance Checklist (Save This)

Before publishing any page, video, or ad:

• ✅ Are we educating, not promising outcomes?
• ✅ Are we avoiding disease-treatment menus and "guarantee" language?
• ✅ Do we disclose uncertainty where science is emerging?
• ✅ Are testimonials non-clinical and non-diagnostic?
• ✅ Does the page read like a resource, not a sales pitch for treating conditions?
• ✅ If running ads, is the landing page exclusively educational?

Want a Media Question Answered on Hyagen Medical?

Hyagen Medical exists to bring clarity to regenerative medicine for patients, clinics, and journalists navigating science, safety, and regulation. Want your question featured or need expert commentary for a story? Email us and join the conversation.

Journalists covering regenerative medicine, FDA enforcement, biotech policy, or patient safety: this episode is built for your beat.

On The Ultimate Assist, John Stockton and Ken Ruettgers sit down with Dr. Harry Adelson (Docere Clinics) and Dr. Chuck Meeker (PhD scientist + patent attorney) to unpack what's really happening inside the stem cell and birth-tissue conversation clinically, legally, and culturally.

We explore bone marrow vs. birth tissue, the innovation-vs.-regulation collision, how FDA language restrictions shape what clinics can say, and the real-world outcomes that keep patients looking for alternatives to surgery. We also address medical tourism, hype vs. evidence, and the public health ripple effects that keep this industry under a microscope.

If you're producing a story, building a segment, or looking for expert commentary, this is a strong starting point.

Want your question featured (or need a quick quote/source)? Email us and join the conversation.

Regenerative medicine is changing the conversation around healthcare. As more patients seek information about peptides, birth tissue-derived products, and other regenerative technologies, the industry is experiencing tremendous growth. But with that growth comes an equally important responsibility: ensuring that patient safety, scientific integrity, and regulatory compliance remain at the center of every conversation.

That was the focus of Hyagen Medical Founder Chuck Meeker, Ph.D., Esq., during his recent appearance on ABC4’s Good Things Utah, where he discussed the importance of helping patients make informed decisions and helping clinics understand today’s regulatory landscape.

At Hyagen Medical, we believe innovation should always be accompanied by education.

Why Patient Safety Must Come Before Hype

Interest in regenerative medicine has expanded rapidly over the past several years. Patients are researching new technologies online, hearing success stories on podcasts, and seeing an increasing number of clinics offering regenerative medicine services.

Unfortunately, public awareness has grown faster than public understanding. Many patients don’t know what questions to ask before selecting a clinic. Others may assume every clinic follows the same quality standards or operates under the same compliance framework.

That’s why education matters. Patient safety begins long before someone walks into an exam room. It starts with accurate information, transparent communication, and choosing providers who value science, ethics, and regulatory compliance.

Education Empowers Better Decisions

During his ABC4 interview, Chuck emphasized that patients deserve more than marketing—they deserve education. Understanding the differences between peptides, birth tissue-derived products, regulatory classifications, and clinic standards allows patients to have more informed conversations with their healthcare providers.

An educated patient is better equipped to ask important questions, including:

• Where are your products sourced?
• Are your products manufactured under applicable FDA regulations?
• How do you educate patients about your products?
• How do you ensure your clinic follows current regulatory standards?
• What quality assurance processes are in place?

These conversations help create transparency while strengthening trust between patients and providers.

FDA Compliance Is a Patient Safety Issue

One of the biggest misconceptions in regenerative medicine is that compliance is simply paperwork. In reality, compliance exists to help protect patients.

Federal regulatory frameworks establish important standards for how certain birth tissue-derived products are manufactured, distributed, and marketed. Understanding those requirements helps clinics operate responsibly while reducing unnecessary regulatory risk.

Responsible clinics recognize that compliance isn’t a barrier to innovation. It’s the foundation for sustainable growth, patient confidence, and long-term credibility.

Building a Higher Standard for Clinics

At Hyagen Medical, our mission extends beyond supplying products. We are committed to helping clinics build compliant, transparent, and patient-centered practices through education, operational guidance, and regulatory clarity.

Our work focuses on helping healthcare providers:

• Better understand current FDA regulatory frameworks
• Strengthen compliant patient communication
• Improve operational integrity
• Build greater patient trust through transparency
• Stay informed as regulatory expectations continue to evolve

When clinics prioritize education alongside compliance, everyone benefits.

Why Responsible Communication Matters

The language used in regenerative medicine matters. Patients deserve clear, honest communication that explains products accurately without creating unrealistic expectations.

At Hyagen Medical, we believe healthcare communication should always be grounded in scientific integrity and responsible education. Our commitment is to help clinics communicate clearly, ethically, and within current regulatory frameworks while empowering patients with information they can trust.

Our Mission

Watching the regenerative medicine industry evolve has been inspiring. The opportunity to improve patient education, elevate professional standards, and encourage responsible innovation has never been greater. Hyagen Medical exists to help move that mission forward.

We are committed to creating meaningful dialogue around patient safety, clinical integrity, regulatory clarity, and transparent communication because these principles should never be optional in healthcare. As public interest in regenerative medicine continues to grow, so does our responsibility to ensure that innovation is matched with education, accountability, and trust.

Download the guide here to go deeper on building confidence through science, education, and integrity.

Thank You to ABC4

We are grateful to ABC4’s Good Things Utah, Producer Krystal Gates, George Severson, and the entire production team for helping bring this important conversation to viewers across Utah. Public education plays an essential role in strengthening healthcare, and we’re honored to contribute to that discussion.

Looking Ahead

The future of regenerative medicine depends on more than scientific advancement. It depends on informed patients. It depends on responsible clinics. It depends on transparent communication. And it depends on organizations willing to raise the standard for an entire industry. At Hyagen Medical, that is the work we’re committed to every day.

Learn More

Whether you’re a patient looking to ask better questions or a clinic seeking trusted education and regulatory guidance, Hyagen Medical is committed to supporting a safer, more transparent future for regenerative medicine. Explore our educational resources, clinic compliance solutions, and patient guides to learn more about building confidence through science, education, and integrity.